Recently, the Yangtze River pharmaceutical group sichuan hai rong pharmaceutical co., LTD. Vigliptin tablets successfully approved (according to the new chemical registration classification of 4 categories, approval number: national medicine approval word 20203360), regarded as through the consistency evaluation! This is the sixth approval that Hailong has obtained through the consistency evaluation, which marks the next step for Yangzijiang Pharmaceutical in the field of chronic diabetes.

This product is suitable for the treatment of type 2 diabetes, the original research company is Novartis. Compared with other DPP-4 inhibitors, Vigliptin is a substrate like enzyme inhibitor, which can inhibit the activity of DPP-4 enzyme for a longer time. Significantly increasing GLP-1 level can better inhibit glucagon level; It also inhibits the generation of endogenous glucose (EGP) after prandial, and the effect is lasting. Vigliptin is deactivated by hydrolysis, which does not affect CYP isozyme, and the possibility of interaction is low. In addition, regardless of the initial single drug therapy, to the combination of oral hypoglycemic agents, and even to the final combination of insulin, vigliptin can meet the medication needs to a certain extent, which can be described as "throughout the whole process".

According to the latest Diabetes Map (9th Edition) released by the International Diabetes Federation (IDF) in 2019, the number of diabetic population in China has reached 116.4 million, ranking first in the world, and the situation of diabetes prevention and control is grim. D Glenn dean piece, means that the Yangtze river pharmaceutical group in the field of diabetes treatment, in addition to tang Lin ® (according to palmer department) and on Sue ® (Glenn urea) blockbuster products, such as adding a major new member, also fill in the Yangtze river pharmaceutical group in the blank in the field of DPP 4 inhibitors, at the same time at the start of the implementation of "difference" planning, It plays an important role in connecting the past and the future. The product is produced by Sichuan Hairong Pharmaceutical Co., Ltd., Yangzijiang Pharmaceutical Group, and is expected to be officially launched in September 2020.